Differential Immunohistochemical Expression of Syndecan-1 and Tumor Necrosis Factor Alpha in Colonic Mucosa of Patients with Crohn’s Disease

REFERENCES

• Murch S.H., Braegger C.P., Walker-Smith J.A., MacDonald T.T. Location of tumor necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease. Gut 1993; 34(12)1705–1709
   PubMed Web of Science ®Google Scholar
• Dionne S., Hiscott J., D’Agata I.D., Duhaime A., Seidman E.G. Quantitative PCR analysis of TNFα and IL-1β mRNA levels in pediatric IBD mucosal biopsies. Dig. Dis. Sci 1997; 42(7)1557–1566
   PubMed Web of Science ®Google Scholar
• Rugtveit J., Nilsen E.M., Bakka A., Carlsen H., Brandtzaeg P. Cytokine profiles differ in newly recruited and resident subsets of mucosal macrophages from inflammatory bowel disease. Gastroenterology 1997; 112(5)1493–1505
   PubMed Web of Science ®Google Scholar
• van Dullemen H.M., van Deventer S.J., Hommes D.W., Bijl H.A., Jansen J., Tytgat G.N., Woody J. Treatment of Crohn’s disease with anti-tumor necrosis factor chimeric monoclonal antibody cA2. Gastroenterology 1995; 109(1)129–135
   PubMed Web of Science ®Google Scholar
• Baert F.J., D’Haens G.R., Peeters M., Hiele M.I., Schaible T.F., Shealy D., Geboes K., Rutgeerts P.J. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn’s ileocolitis. Gastroenterology 1999; 116(1)22–28
   PubMed Web of Science ®Google Scholar
• Haier J., Nicolson G.L. Cell biology and clinical implications of adhesion molecules in colorectal diseases: colorectal cancers, infections and inflammatory bowel diseases. Clin. Exp. Metast 2000; 18(5)623–638
   PubMed Web of Science ®Google Scholar
• Neurath M.F., Schurmann G. Immunopathogenesis of inflammatory bowel diseases. Chirurg 2000; 71(1)30–40
   PubMed Web of Science ®Google Scholar
• Day R., Ilyas M., Daszak P., Talbot I., Forbes A. Expression of Syndecan-1 in inflammatory bowel disease and a possible mechanism of heparin therapy. Dig. Dis. Sci 1999; 44(12)2508–2515
   PubMed Web of Science ®Google Scholar
• Saunders S., Jalkanen M., O’Farrell S., Bernfield M. Molecular cloning of syndecan, an integral membrane proteoglycan. J. Cell Biol 1989; 108(2)1547–1556
   PubMed Web of Science ®Google Scholar
• Day R., Forbes A. Heparin, cell adhesion, and pathogenesis of inflammatory bowel diasease. Lancet July 3, 1999; 354: 62–64
   PubMed Web of Science ®Google Scholar
• Day R., Mitchell T., Knight S., Forbes A. Regulation of epithelial syndecan-1 expression by inflammatory cytokine. Cytokines 2003; 21(5)224–233
   Google Scholar
• Kainulainen V., Nelimarkka L., Järveläinen H., Laato M., Jalkanen M., Elenius K. Suppression of Syndecan-1 expression in endothelial cells by tumor necrosis factor-α. J. Biol. Chem 1996; 271(31)18759–18766
   PubMed Web of Science ®Google Scholar
• Ierardi E., Di Leo A., Barone M., Marangi S., Burattini O., Panarese A., Margiotta M., Francavilla R., Panella A., Francavilla A., Cuomo R. Tumor necrosis factor alpha and apoptosis related progressive gastric damage: a possibile mechanism of immune system involvement in epithelial turnover regulation. Immunopharmacol. Immunotoxicol 2003; 25(2)203–211
   PubMed Web of Science ®Google Scholar
• Ierardi E., Monno R.A., Gentile A., Francavilla R., Burattini O., Marangi S., Pollice L., Francavilla A. Helicobacter heilmannii gastritis: a histological and immunohistochemical trait. J. Clin. Pathol 2001; 54(11)774–777
   PubMed Web of Science ®Google Scholar
• Day R., Hao X., Ilyas M., Daszak P., Talbot I., Forbes A. Changes in the expression of syndecan-1 in the colorectal adenoma-carcinoma sequence. Virchows Arch 1999; 434(2)121–125
   PubMed Web of Science ®Google Scholar
• Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 1998; 115(1)182–205
   PubMed Web of Science ®Google Scholar
• Wyatt J., Vogelsang H., Hubl W., Waldhoer T., Lochs H. Intestinal permeability and the prediction of relapse in Crohn’s disease. Lancet June 5, 1993; 341: 1437–1439
   PubMed Web of Science ®Google Scholar
• Yayon A., Klagsbrun M., Esko J., Leder P., Ornitz D. Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell 1991; 64(34)841–848
   PubMed Web of Science ®Google Scholar
• Dignass A.U. Mechanisms and modulation of intestinal epithelial repair Inflamm. Bowel Dis 2001; 7(1)68–77
   PubMed Web of Science ®Google Scholar
• Ruemmele F.M., Seidman E.G. Cytokine-intestinal epithelial cell interactions: implication for immune-mediated bowel disorders. Acta Paediatr. Sin 1998; 39(1)1–8
   Google Scholar
• Ierardi E., Principi M., Burattini O., Marangi S., Panarese A., Francavilla A. Pattern of apoptosis in Crohn’s disease: a singular aspect?. Dig. Liver. Dis 2001; 33(7)614–615
   PubMedGoogle Scholar
• Braegger C.P., Nicholls S., Murch S.H., Stephens S., MacDonald T.T. Tumor necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet Jan 11, 1992; 339: 89–91
   PubMed Web of Science ®Google Scholar
• Papadakis K.A., Targan S.R. Tumor necrosis factor: biology and therapeutic inhibitors. Gastroenterology 2000; 119(4)1148–1457
   PubMed Web of Science ®Google Scholar
• Targan S.R., Hanauer S.B., van Deventer S.J., Mayer L., Present D.H., Braakman T., DeWoody K.L., Schaible T.F., Rutgeerts P.J. A short term study of chimeric monoclonal antibody cA2 to tumour necrosis factor alpha for Crohn’s disease. N. Engl. J. Med 1997; 337(15)1029–1035
   PubMed Web of Science ®Google Scholar
• Rutgeerts P., D’Haens G., Targan S., Vasiliauskas E., Hanauer S.B., Present D.H., Mayer L., Von Hogezand R.A., Braakman T., DeWoody K.L., Schaible T.F., Van Deventer S.J. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn’s disease. Gastroenterology 1999; 117(4)761–769
   PubMed Web of Science ®Google Scholar
• Sartor R.B. Current concepts of the etiology and pathogenesis of ulcerative colitis and Crohn’s disease. Gastroenterol. Clin. North. Am 1995; 24(3)475–507
   PubMed Web of Science ®Google Scholar
• MacDonald T.T., Hutchings P., Choy M., Murch S., Cooke A. Tumor necrosis factor alpha and interferon-gamma productions measured at the single cell level in normal and inflamed human intestine. Clin. Exp. Immunol 1990; 81(2)301–305
   PubMed Web of Science ®Google Scholar
• Perry I., Tselepis C., Hoyland J., Iqbal T., Sanders S., Cooper I.J., Jankowski J.A. Reduced cadherin/catenin complex expression in celiac disease can be reproduced in vitro by cytokine stimulation. Lab. Invest 1999; 79(12)1489–1499
   PubMed Web of Science ®Google Scholar
• Yacyshyn B.R., Barish C., Goff J., Dalke D., Gaspari M., Yu R., Tami J., Dorr F.A., Sewell K.L. Dose ranging pharmacokinetic trial of high-dose alicaforsen (intercellular adhesion molecule-1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn’s disease. Aliment Pharmacol. Ther 2002; 16(10)1761–1770
   PubMed Web of Science ®Google Scholar
• Folwaczny C., Wiebecke B., Loeschke K. Unfractioned heparin in the therapy of patients with highly active inflammatory bowel disease. Am. J. Gastroenterol 1999; 94(6)1551–1555
   PubMed Web of Science ®Google Scholar